Gamma-Acetylenic GABA in tardive dyskinesia.

Daniel Casey, J. Gerlach, G. Magelund, T. R. Christensen

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

gamma-Acetylenic GABA, a drug that increases brain GABA via GABA transaminase inhibition, was evaluated in a blind placebo-controlled trial in 10 patients with stable tardive dyskinesia. Drug effects during active treatment (75 to 225 mg/day) and pre- and post-treatment placebo periods were determined by scoring TD and parkinsonian symptoms recorded weekly on videotape during standardized examinations. GAG significantly reduced TD (p <0.01), although the effect was moderate, in patiens concurrently taking neuroleptics and increased preexisting parkinsonism. The greatest antihyperkinetic effects tended to occur in patients receiving higher neuroleptic doses, suggesting an interaction between GABA and dopamine. There was no effect of GAG on psychiatric symptoms. Further investigations with GAG and similar agents will be important tools for investigating GABA in movement disorders and other central nervous system dysfunctions.

Original languageEnglish (US)
Pages (from-to)577-580
Number of pages4
JournalAdvances in biochemical psychopharmacology
Volume24
StatePublished - 1980
Externally publishedYes

Fingerprint

gamma-Aminobutyric Acid
Antipsychotic Agents
Placebos
4-Aminobutyrate Transaminase
Videotape Recording
Movement Disorders
Parkinsonian Disorders
Pharmaceutical Preparations
Psychiatry
Dopamine
Therapeutics
Central Nervous System
Brain
4-amino-5-hexynoic acid
Tardive Dyskinesia

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Casey, D., Gerlach, J., Magelund, G., & Christensen, T. R. (1980). Gamma-Acetylenic GABA in tardive dyskinesia. Advances in biochemical psychopharmacology, 24, 577-580.

Gamma-Acetylenic GABA in tardive dyskinesia. / Casey, Daniel; Gerlach, J.; Magelund, G.; Christensen, T. R.

In: Advances in biochemical psychopharmacology, Vol. 24, 1980, p. 577-580.

Research output: Contribution to journalArticle

Casey, D, Gerlach, J, Magelund, G & Christensen, TR 1980, 'Gamma-Acetylenic GABA in tardive dyskinesia.', Advances in biochemical psychopharmacology, vol. 24, pp. 577-580.
Casey D, Gerlach J, Magelund G, Christensen TR. Gamma-Acetylenic GABA in tardive dyskinesia. Advances in biochemical psychopharmacology. 1980;24:577-580.
Casey, Daniel ; Gerlach, J. ; Magelund, G. ; Christensen, T. R. / Gamma-Acetylenic GABA in tardive dyskinesia. In: Advances in biochemical psychopharmacology. 1980 ; Vol. 24. pp. 577-580.
@article{eac73b7bf59f46c8aae76a9a8e82ab2c,
title = "Gamma-Acetylenic GABA in tardive dyskinesia.",
abstract = "gamma-Acetylenic GABA, a drug that increases brain GABA via GABA transaminase inhibition, was evaluated in a blind placebo-controlled trial in 10 patients with stable tardive dyskinesia. Drug effects during active treatment (75 to 225 mg/day) and pre- and post-treatment placebo periods were determined by scoring TD and parkinsonian symptoms recorded weekly on videotape during standardized examinations. GAG significantly reduced TD (p <0.01), although the effect was moderate, in patiens concurrently taking neuroleptics and increased preexisting parkinsonism. The greatest antihyperkinetic effects tended to occur in patients receiving higher neuroleptic doses, suggesting an interaction between GABA and dopamine. There was no effect of GAG on psychiatric symptoms. Further investigations with GAG and similar agents will be important tools for investigating GABA in movement disorders and other central nervous system dysfunctions.",
author = "Daniel Casey and J. Gerlach and G. Magelund and Christensen, {T. R.}",
year = "1980",
language = "English (US)",
volume = "24",
pages = "577--580",
journal = "Advances in biochemical psychopharmacology",
issn = "0065-2229",

}

TY - JOUR

T1 - Gamma-Acetylenic GABA in tardive dyskinesia.

AU - Casey, Daniel

AU - Gerlach, J.

AU - Magelund, G.

AU - Christensen, T. R.

PY - 1980

Y1 - 1980

N2 - gamma-Acetylenic GABA, a drug that increases brain GABA via GABA transaminase inhibition, was evaluated in a blind placebo-controlled trial in 10 patients with stable tardive dyskinesia. Drug effects during active treatment (75 to 225 mg/day) and pre- and post-treatment placebo periods were determined by scoring TD and parkinsonian symptoms recorded weekly on videotape during standardized examinations. GAG significantly reduced TD (p <0.01), although the effect was moderate, in patiens concurrently taking neuroleptics and increased preexisting parkinsonism. The greatest antihyperkinetic effects tended to occur in patients receiving higher neuroleptic doses, suggesting an interaction between GABA and dopamine. There was no effect of GAG on psychiatric symptoms. Further investigations with GAG and similar agents will be important tools for investigating GABA in movement disorders and other central nervous system dysfunctions.

AB - gamma-Acetylenic GABA, a drug that increases brain GABA via GABA transaminase inhibition, was evaluated in a blind placebo-controlled trial in 10 patients with stable tardive dyskinesia. Drug effects during active treatment (75 to 225 mg/day) and pre- and post-treatment placebo periods were determined by scoring TD and parkinsonian symptoms recorded weekly on videotape during standardized examinations. GAG significantly reduced TD (p <0.01), although the effect was moderate, in patiens concurrently taking neuroleptics and increased preexisting parkinsonism. The greatest antihyperkinetic effects tended to occur in patients receiving higher neuroleptic doses, suggesting an interaction between GABA and dopamine. There was no effect of GAG on psychiatric symptoms. Further investigations with GAG and similar agents will be important tools for investigating GABA in movement disorders and other central nervous system dysfunctions.

UR - http://www.scopus.com/inward/record.url?scp=0018873480&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018873480&partnerID=8YFLogxK

M3 - Article

C2 - 6105803

AN - SCOPUS:0018873480

VL - 24

SP - 577

EP - 580

JO - Advances in biochemical psychopharmacology

JF - Advances in biochemical psychopharmacology

SN - 0065-2229

ER -